MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Format: Artigo
Jezik:Russo
Izdano: QUASAR, LLC 2018-03-01
Serija:Issledovaniâ i Praktika v Medicine
Teme:
bladder cancer
pd-1
pd-l1
immunotherapy
atezolizumab
nivolumab
pembrolizumab
avelumab
durvalumab
Online dostop:https://www.rpmj.ru/rpmj/article/view/246
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki